J Cosmet Dermatol:微针治疗黄褐斑后外用氨甲环酸与维生素c的疗效和安全性比较

2022-08-09 sunshine MedSci原创

黄褐斑是一种常见的后天性对称分布的日光暴露皮肤的色素沉着斑,大大影响患者的生活质量和心理感受。皮肤微针疗法作为一种经皮给药系统,有利于增白剂渗透到皮肤深层。

黄褐斑是一种常见的后天性对称分布的日光暴露皮肤的色素沉着斑,大大影响患者的生活质量和心理感受。皮肤微针疗法作为一种经皮给药系统,有利于增白剂渗透到皮肤深层。近日,发表于J Cosmet Dermatol的一项分脸的前瞻性、随机的非对照研究评估了微针疗法治疗黄褐斑后外用氨甲环酸与外用维生素C的疗效和安全性。

研究共纳入20名面部黄褐斑患者,右侧脸在皮秒微针后用局部氨甲环酸治疗,而左侧脸在皮秒微针后用局部维生素C治疗。每2周做一次治疗,共6次。治疗前后都做了Hemi-MASI评分和皮肤镜检查。

 

结果显示,两侧面部的Hemi-MASI评分在治疗后都有所下降。医生的总体评价方面,右侧的黄褐斑皮损改善情况比左侧的好,但是治疗后右侧和左侧的差异没有统计学意义(P=0.346)。 关于治疗后临床改善的等级,右侧脸部(TXA)有5名患者(25%)有非常好的改善,6名患者(30%)有优秀的改善。左侧脸部(维生素C)有7名患者(35%)有非常好的改善,2名患者(10%)有非常好的改善。此外,皮肤镜检查显示两侧的色素病变都有所改善,氨甲环酸治疗的一侧的血管成分也有所改善。

综上所述,该研究结果表明,在皮秒微针治疗后局部应用氨甲环酸或维生素C是一种有效和安全的黄褐斑治疗技术,副作用最小。但由于其血管作用,在微针治疗后用氨甲环酸治疗在血管成分的外观改善上具有优势。研究的局限性在于研究组人数少,随访时间短,未来将进一步研究不同浓度的氨甲环酸和维生素c治疗黄褐斑的方法,还应评估其他联合治疗方法的疗效与安全性。

 

原始出处:

 

Yasmina El Attar, et al., Efficacy and Safety of tranexamic acid versus vitamin c after microneedling in treatment of melasma: Clinical and Dermoscopic study. J Cosmet Dermatol. 2022 Jul;21(7):2817-2825. doi: 10.1111/jocd.14538. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897048, encodeId=6f18189e048b8, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Dec 26 17:14:02 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721212, encodeId=53391e21212bc, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Oct 14 02:14:02 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783642, encodeId=208d1e8364249, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun Nov 06 21:14:02 CST 2022, time=2022-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237565, encodeId=d26e123e565cd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3a31581237, createdName=zwddoctor, createdTime=Tue Aug 09 14:10:21 CST 2022, time=2022-08-09, status=1, ipAttribution=)]
    2022-12-26 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897048, encodeId=6f18189e048b8, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Dec 26 17:14:02 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721212, encodeId=53391e21212bc, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Oct 14 02:14:02 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783642, encodeId=208d1e8364249, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun Nov 06 21:14:02 CST 2022, time=2022-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237565, encodeId=d26e123e565cd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3a31581237, createdName=zwddoctor, createdTime=Tue Aug 09 14:10:21 CST 2022, time=2022-08-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897048, encodeId=6f18189e048b8, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Dec 26 17:14:02 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721212, encodeId=53391e21212bc, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Oct 14 02:14:02 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783642, encodeId=208d1e8364249, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun Nov 06 21:14:02 CST 2022, time=2022-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237565, encodeId=d26e123e565cd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3a31581237, createdName=zwddoctor, createdTime=Tue Aug 09 14:10:21 CST 2022, time=2022-08-09, status=1, ipAttribution=)]
    2022-11-06 tcm99hq
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897048, encodeId=6f18189e048b8, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Dec 26 17:14:02 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721212, encodeId=53391e21212bc, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Fri Oct 14 02:14:02 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783642, encodeId=208d1e8364249, content=<a href='/topic/show?id=f6c9511ec2' target=_blank style='color:#2F92EE;'>#CoSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5117, encryptionId=f6c9511ec2, topicName=CoSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun Nov 06 21:14:02 CST 2022, time=2022-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237565, encodeId=d26e123e565cd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d3a31581237, createdName=zwddoctor, createdTime=Tue Aug 09 14:10:21 CST 2022, time=2022-08-09, status=1, ipAttribution=)]
    2022-08-09 zwddoctor

    学习

    0

相关资讯

Clin Nutr:浙大一附院郑良荣团队发现高维C水平可降低心源性卒中和阿尔兹海默症风险!

高维生素C水平与心源性卒中和阿尔兹海默症风险降低相关

Crit Care:维生素C可改善感染性休克患者的微血管反应性和外周组织灌注

在复苏的感染性休克患者中,无论血浆中的维生素C水平如何,维生素C补充剂都能改善外周组织灌注和微血管反应性。

过节也别忘了多吃蔬菜水果!蔬果里的TA或有效降低心血管疾病风险!

Scientifc Reports:膳食抗氧化剂摄入量与心血管疾病之间的关系。

NEJM:脓毒症人群使用高剂量VitC有害无益?

现在维生素C(又称L-抗坏血酸)在脓毒症治疗中的作用正在演变。维生素C的大多数已知生物学功能都与其抗氧化性能有关。它能阻断在脓毒症等不同应激状态下形成的活性氧(ROS),并能损伤细胞蛋白质、脂类、DN